Skip to main content
OpenTrials
Completed

NCT Number: NCT03337802

Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring

The first 1,000 days of life, from the conception to 24 months, are crucial to achieve long-term health outcomes and represent a strategic period to intervene under prevention and public health perspective. Nutritional exposures during this critical period of life can influence the future disease susceptibility. Maternal diet during pregnancy has been linked to offspring overweight/obesity risk and it could represent a potential target for overweight/obesity prevention. The Mediterranean Diet (MD) is considered one of the healthiest dietary models, which impacts beneficially the gut microbiome (GM), providing high amounts of fiber, antioxidants polyphenols and vitamins, and a balanced ratio of essential fatty acids (ω6:ω3). Notably, the MD beneficial effects are due to the synergistic and interactive combinations of nutrients, and the modulation of gene expression through epigenetic changes. Unofrtunately, the MD mechanisms during pregnancy in the prevention of childhood overweight/obesity are not yet fully known.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Food Allergy Food Hypersensitivity Hypersensitivity Hypersensitivity, Immediate Immune System Diseases

Age range

20 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Naples Federico II

Naples, 80131, Italy

About this study

The PREMEDI study has been designed to evaluate the effects of Mediterranean Diet during pregnancy on the occurrence of overweight/obesity at 24 months in the offspring.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women
  • caucasian ethnicity
  • aged between 20 and 35 years

Exclusion criteria

  • proven presence of infections during pregnancy and at delivery,
  • twin pregnancy,
  • ongoing malignancies,
  • major gastrointestinal tract malformations,
  • immunodeficiencies,
  • diabetes and other chronic diseases at each organ or apparatus level,
  • chronic intestinal inflammatory diseases,
  • gastrointestinal function disorders,
  • celiac disease;
  • history of abdominal surgery with intestinal resection,
  • neuropsychiatric disorders,
  • central nervous system disorders,
  • vegan diet.

Treatment and study plan

Mediterranean Diet

Behavioral

The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.

Primary outcomes

  1. The effects of Mediterranean Diet in pregnancy on the occurrence of overweight/obesity at 24 months in the offspring

    Time frame: After 24 months from the delivery

    The children body growth indices are evaluated at 24 months

Secondary outcomes

  1. The effect of Mediterranean Diet pregnancy on the composition of maternal gut microbiota through analysis of gut microbiota composition.

    Time frame: after 9 months (at the end of the pregnancy)

    Fecal bacteria DNA will be extracted using standard technique outlined by the Earth Microbiome Project. 16S V4-region amplicon libraries will be produced using previously described primers and sequenced using the IlluminaMiSeqplatform (150bpx2). Bacterial load will be determined by qPCR using a standard curve derived from a plasmid containing a single copy of the 16S rRNAencoding gene. Sequence data has been deposited in MG RAST under accession numbers 4571868.3-4571924.3 and project number 10023. Paired end reads will be quality trimmed and processed for OTU (operational taxonomic unit) clustering using UPARSE pipeline, set at 0.97% identity cutoff. Taxonomic status will be assigned to the high quality (<1% incorrect bases) candidate OTUs using the "parallel_assign_taxonomy_rdp.py" script of QIIME software. Multiple sequence alignment and phylogenetic reconstruction will be performed using PyNast and FastTree.

  2. The effect of Mediterranean diet in pregnancy on the production of short chain fatty acids (butyrate and propionate) in the intestinal tract.

    Time frame: after 9 months (at the end of the pregnancy)

    Fecal SCFAs concentration Frozen feces weighing 1g will be diluted with saline solution, vortexed, and centrifuged. Supernatants will be filtered and stored at -20°C until analysis. Frozen fecal extracts will be acidified and extracted in duplicate. A quantity of the pooled extract containing acidified butyrate, propionate or acetate will be transferred into a 2ml glass vial and loaded onto an Agilent Technologies 7890 gas chromatograph (GC) system. Detection will be achieved using a flame ionization detector. Peaks will be identified using a mixed external standard and quantified by peak height/internal standard ratio. To examine whether fecal butyrate levels correlates with bacterial diversity (Shannon diversity index) and evenness (Pielou's evenness index) and abundance patterns across multiple groups we will calculate the Spearman correlation using the cor.test function implemented in R (http://www.r-project.org/

  3. The adherence to Mediterranean Diet in the enrolled women

    Time frame: from 0 to 9 months (at the end of pregnancy)

    Women Mediterranean Diet adherence score is evaluated through the "Med Diet Score"

  4. The effect of dietary counseling on dietary habits

    Time frame: from 0 to 9 months (at the end of pregnancy)

    The diet composition in macro- and micronutrients is evaluated

  5. The effect of Mediterranean diet in pregnancy on the maternal weight gain and complications

    Time frame: from 0 to 9 months (at the end of pregnancy)

    To evaluate the effect of Mediterranean diet in pregnancy on the maternal weight gain and complications (gestational hypertension, infections, gestational diabetes, preeclampsia, use of cesarean)

  6. The effect of Mediterranean diet in pregnancy on perinatal and fetal complications

    Time frame: from 0 to 9 months (at the end of pregnancy)

    Perinatal and fetal complications occurrence are evaluated

  7. The effect of Mediterranean Diet in pregnancy on the duration of breastfeeding and the composition of breast milk

    Time frame: from 0 to 4 months lactation

    The effect of Mediterranean Diet in pregnancy on the duration of breastfeeding and the composition of breast milk (short chain fatty acids, bacterial DNA, adipocytokines.

  8. The effect of Mediterranean Diet on the occurrence of allergies and use of antibiotics in the first 2 years of life.

    Time frame: Every 6 months from offspring birth to 2 years

    The occurrence of allergies and the use of antibiotics in the first 2 years of life are evaluated

  9. The effect of Mediterranean Diet on the epigenetic modulation of genes involved in the regulation of immune system and metabolic pathways in the offspring

    Time frame: At delivery

    The evaluation of the effect of Mediterranean Diet during pregnancy on the epigenetic modulation of genes involved in the immune system and metabolic pathways in the offspring through the cord blood epigenome-wide association study

Sponsors and collaborators

Lead sponsor

Federico II University

Other

Registry information

Official study title

Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity at 24 Months in the Offspring

Acronym: PREMEDI

Important dates

Study start
2017
Primary completion
2020
Study completion
2021
First posted
Nov 9, 2017
Registry last updated
Jun 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.